What's Happening?
Frank Tagliaferri, Ph.D., the Chief Scientific Officer of Pace Life Sciences, is set to participate in a panel session at the Advancing Drug Development Forum (ADDF) on December 11, 2025. The session, titled 'Beyond Rule of 5 (bRo5) Live Lab,' will be held at the UMASS Club and will focus on the oral delivery of complex molecules. This workshop aims to bring together industry experts to discuss advancements in drug development, particularly for non-traditional molecules. Tagliaferri will contribute to discussions on enabling advanced technologies for the development of these challenging modalities. He emphasizes the unique challenges posed by biologics and other large, complex molecules in oral delivery due to their structural sensitivities
and poor bioavailability. The event is part of a broader effort to innovate and collaborate on solutions that make oral delivery commercially viable for complex molecules.
Why It's Important?
The participation of Frank Tagliaferri in this forum highlights the ongoing efforts in the pharmaceutical industry to overcome significant challenges in drug delivery. The focus on non-traditional molecules is crucial as these represent a growing segment of therapeutic agents with potential benefits in treating complex diseases. Successfully developing oral delivery methods for these molecules could revolutionize patient treatment options, making therapies more accessible and improving patient compliance. This initiative also underscores the importance of collaboration and innovation in the pharmaceutical sector, as overcoming these challenges requires a concerted effort from various stakeholders, including researchers, developers, and regulatory bodies.
What's Next?
Following the panel session, it is expected that the insights and discussions will lead to further research and development initiatives aimed at advancing oral drug delivery technologies. Companies like Pace Life Sciences may continue to invest in state-of-the-art facilities and collaborative projects to push the boundaries of what is possible in drug formulation and delivery. The outcomes of such forums could influence future regulatory guidelines and industry standards, potentially accelerating the availability of new therapies in the market.
